Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

This study is testing whether combining two targeted drugs — osimertinib and carotuximab — can improve outcomes in people with advanced lung cancer driven by EGFR mutations, including those whose cancer has stopped responding to osimertinib alone. **You may be eligible if...** - You have been diagnosed with Stage IV or metastatic non-squamous non-small cell lung cancer (NSCLC) with an EGFR activating mutation - Your cancer has progressed on at least one prior EGFR-targeted therapy, or specifically on osimertinib - Your overall health allows you to participate in a clinical trial **You may NOT be eligible if...** - You have active brain metastases that are not stable - You have significant heart problems, including a prolonged QT interval - You are on blood thinners or have active bleeding - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.